Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

Ret Proto-Oncogene Antikörper (AA 896-1063)

RET Reaktivität: Human WB, ELISA Wirt: Maus Monoclonal 6E4C4 unconjugated
Produktnummer ABIN966962
  • Target Alle Ret Proto-Oncogene (RET) Antikörper anzeigen
    Ret Proto-Oncogene (RET)
    Bindungsspezifität
    • 27
    • 21
    • 21
    • 16
    • 15
    • 15
    • 15
    • 14
    • 9
    • 8
    • 8
    • 8
    • 7
    • 6
    • 6
    • 6
    • 6
    • 6
    • 6
    • 6
    • 5
    • 4
    • 4
    • 4
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 896-1063
    Reaktivität
    • 183
    • 100
    • 81
    • 5
    • 3
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Human
    Wirt
    • 206
    • 22
    • 2
    • 1
    • 1
    • 1
    Maus
    Klonalität
    • 201
    • 32
    Monoklonal
    Konjugat
    • 90
    • 18
    • 14
    • 13
    • 10
    • 9
    • 9
    • 9
    • 9
    • 9
    • 9
    • 8
    • 5
    • 5
    • 5
    • 5
    • 5
    • 1
    Dieser Ret Proto-Oncogene Antikörper ist unkonjugiert
    Applikation
    • 191
    • 102
    • 66
    • 65
    • 58
    • 28
    • 22
    • 16
    • 15
    • 10
    • 4
    • 3
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    Western Blotting (WB), ELISA
    Aufreinigung
    Ascitic fluid
    Immunogen
    Purified recombinant fragment of RET (aa896-1063) expressed in E. Coli.
    Klon
    6E4C4
    Isotyp
    IgG1
    Top Product
    Discover our top product RET Primärantikörper
  • Applikationshinweise
    Western Bloting: 1/500 - 1/2000.
    ELISA: Propose dilution 1/10000.
    Not yet tested in other applications.
    Determining optimal working dilutions by titration test.
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Konservierungsmittel
    Sodium azide
    Vorsichtsmaßnahmen
    This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Lagerung
    4 °C
  • Target
    Ret Proto-Oncogene (RET)
    Andere Bezeichnung
    RET (RET Produkte)
    Synonyme
    c-ret antikoerper, cret antikoerper, etID315074.13 antikoerper, ret1 antikoerper, wu:fd13h01 antikoerper, X-ret antikoerper, ret-A antikoerper, xret antikoerper, RET antikoerper, MTC1 antikoerper, CDHF12 antikoerper, CDHR16 antikoerper, HSCR1 antikoerper, MEN2A antikoerper, MEN2B antikoerper, PTC antikoerper, RET-ELE1 antikoerper, RET51 antikoerper, RET9 antikoerper, c-Ret antikoerper, ret proto-oncogene receptor tyrosine kinase antikoerper, ret proto-oncogene S homeolog antikoerper, ret proto-oncogene antikoerper, ret antikoerper, ret.S antikoerper, RET antikoerper, Ret antikoerper
    Hintergrund
    RET (ret proto-oncogene) is a member of the cadherin superfamily and a receptor tyrosine kinase, which are cellsurface molecules that transduce signals for cell growth and differentiation. It can undergo oncogenic activation in vivo and in vitro by cytogenetic rearrangement. Ligands that bind the Ret receptor include the glial cell line-derived neurotropic factor (GDNF) and its congeners neurturin, persephin and artemin. Alterations in the corresponding Ret gene are associated with diseases including papillary thyroid carcinoma, multiple endocrine neoplasia (type 2A and 2B), familial medullary thyroid carcinoma and a congenital developmental disorder known as Hirschsprung disease. The Tyr905 residue located in the Ret kinase domain plays a crucial role in Ret catalytic and biological activity. Substitution of Phe for Tyr905 dramatically inhibits Ret autophosphorylation activity.
    Synonyms: RET
    Gen-ID
    5979
    Pathways
    RTK Signalweg, Dopaminergic Neurogenesis, Regulation of Cell Size, Tube Formation
Sie sind hier:
Kundenservice